Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard, Francois-Clement;Kaklamani, Virginia G;Neven, Patrick;Streich, Guillermo;Bardia, Aditya;et.al.
(2023) Journal of clinical oncology — Vol. 41, n° 23, p. 3962 (2023)

Files

2023_Bidard_J_Clin_Oncol_erratum.pdf
  • Open Access
  • Adobe PDF
  • 78.23 KB
Download

Details

Authors
  • Bidard, Francois-Clement
    Author
  • Kaklamani, Virginia G
    Author
  • Neven, Patrick
    Author
  • Streich, Guillermo
    Author
  • Taylor, DonatienneUCLouvain
    Author
  • Bardia, Aditya
    Author
Show more
Abstract
(en) The October 1, 2022 article by Bidard et al entitled “Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial” (J Clin Oncol 10.1200/JCO.22.00338) was published with errors.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., Khong, H., Kocsis, J., Dalenc, F., Dillon, P. M., Babu, S., Waters, S., Deleu, I., García Sáenz, J. A., Bria, E., et al. (2023). Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology, 41(23), 3962. https://doi.org/10.1200/JCO.23.01239 (Original work published 2023)